Meyer B H, Müller F O, Hundt H K, Grigoleit H G, Hajdu P, Heptner W
S Afr Med J. 1981 Jun 13;59(25):891-3.
Twelve healthy male volunteers participated in an open cross-over study designed to test whether two fixed-dose combination formulations of penbutolol (40 mg) and furosemide (20 mg), an ordinary and a film-coated tablet, are bio-equivalent. Penbutolol capsules (40 mg) and 20 mg furosemide tablets (Lasix; Hoechst) served as reference formulations. The maximum concentration of furosemide was significantly depressed in the case of fixed-dose combinations, reflecting a possible pharmacokinetic interaction between penbutolol and furosemide. However, the area under the concentration versus time curve for furosemide and its cumulative urinary excretion and diuretic effect were not influenced by penbutolol. On the basis of plasma concentration versus time data and urinary parameters, the two fixed-dose formulations are bio-equivalent.
12名健康男性志愿者参与了一项开放交叉研究,该研究旨在测试喷布洛尔(40毫克)和呋塞米(20毫克)的两种固定剂量复方制剂(普通片剂和薄膜包衣片)是否生物等效。喷布洛尔胶囊(40毫克)和20毫克呋塞米片(速尿;赫斯特公司)用作参比制剂。在固定剂量复方制剂的情况下,呋塞米的最大浓度显著降低,这反映了喷布洛尔和呋塞米之间可能存在药代动力学相互作用。然而,呋塞米的血药浓度-时间曲线下面积及其累积尿排泄量和利尿作用不受喷布洛尔的影响。基于血药浓度-时间数据和尿液参数,两种固定剂量制剂生物等效。